BOSTON, July 7 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced
today the initiation of the next phase of the Company's program to develop
tetracycline-derived antimalarial therapeutics for treatment and prophylaxis
of malaria. Under a Phase II Small Business Innovative Research (SBIR) grant
from the National Institute of Allergy and Infectious Diseases (NIAID),
Paratek will receive approximately $1 million for each of two years to develop
oral agents against Plasmodium falciparum, the parasite responsible for the
most common and deadly form of malaria.
The Phase II grant was awarded to Paratek as a result of earlier studies
demonstrating the potential for the development of improved tetracycline-based
compounds for use in the fight against malaria. These earlier studies were
conducted in collaboration with Dr. Philip Rosenthal, Director of Pediatric
Hepatology and a professor of Pediatrics and Surgery at the University of
California, San Francisco. The focus of the proposed studies under the Phase
II grant will be to further optimize the compounds with the goal of selecting
preclinical candidates at the end of the two years.
According to Dr. Michael Draper, Associate Director at Paratek,
"Tetracyclines are already an important class of drug in the fight against
malaria, yet their broad-spectrum antibacterial activity is a disadvantage
that potentially contributes to the problem of antibacterial resistance. By
applying innovative chemistries to minimize the antibacterial effects and
improve the antimalarial potency of compounds, we have been able to create
novel tetracyclines that are optimized for use in non-bacterial conditions
Malaria infects an estimated 300 to 500 million people around the world.
P. falciparum infections, in particular, kill more than one million annually,
mostly young children and pregnant women. Just as numerous bacterial
pathogens are outwitting the latest antibiotics, so too are malarial parasites
increasingly resistant to available medications.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek's lead programs are advancing novel compounds
that can circumvent or block bacterial resistance, as well as drugs that can
prevent infection by interfering with Multiple Adaptational Response (MAR)
mechanisms in bacteria. Out of these efforts, Paratek has discovered a new
class of antibiotics, the aminomethylcyclines that target the need for new and
potent antibacterials to overcome the problem of rapidly growing bacterial
resistance. The Company's lead antibiotic clinical candidate, PTK 0796/BAY
73-7388, the first product from this class, is being developed in a
collaborative partnership with Bayer HealthCare AG.
Outside the antibacterial therapeutic area, Paratek has also established
an internal effort to exploit its novel families of compounds and their unique
mechanism of action in selected anti-inflammatory and neurodegenerative
conditions. Paratek has an active chemical synthesis effort to produce novel
and diverse small molecules, with the goal of developing non-antibacterial
products with improved activity in serious diseases based upon a growing body
of clinical and basic research supporting this approach.
Paratek is privately held and headquartered in Boston, Massachusetts, USA.
For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.